Haemonetics Seeks Shareholder Approval for Significant Equity Plan Expansion
Summary
Haemonetics filed its definitive proxy statement, seeking shareholder approval to expand its equity incentive plans, which would increase potential share dilution from 6.47% to 14.69%.
Key Events
-
Equity Plan Expansion Proposed
Shareholders will vote on increasing the share reserve for the 2019 Long-Term Incentive Compensation Plan by 4.68 million additional shares. This would raise the potential overhang (shares subject to awards or available for future grants relative to total shares outstanding) from approximately 6.47% to 14.69%.
-
Employee Stock Purchase Plan Extended
The 2007 Employee Stock Purchase Plan is proposed to be extended through December 31, 2036. Approximately 1.0 million shares remain available under this plan, representing an additional 2.3% potential dilution if fully utilized.
-
Annual Meeting Proposals
Other proposals for the Annual Meeting on July 24, 2026, include the election of eight director nominees, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm.
Analysis
Haemonetics is asking shareholders to approve amendments to its long-term incentive plan and employee stock purchase plan. The proposed changes would significantly increase the number of shares available for equity awards, raising the potential dilution (overhang) from 6.47% to 14.69%. This substantial increase in the share pool, valued at approximately $368 million for the Long-Term Incentive Plan alone, is intended to support employee incentives and retention for the next 2-4 years.
At the time of this filing, HAE was trading at $78.71 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $47.32 to $87.32. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.